A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Daniel Peter Petrylak, Nicholas J. Vogelzang, Gurkamal S. Chatta, Mark T. Fleming, David C. Smith, Leonard Joseph Appleman, Arif Hussain, Manuel Modiano, Parminder Singh, Scott T. Tagawa, Ira Gore, Edward Francis McClay, Anthony E. Mega, A. Oliver Sartor, Bradley G. Somer, Raymond Couric Wadlow, Neal D. Shore, Nancy Stambler, Vincent A. DiPippo, Robert Joseph Israel
Institutions: Yale University, Carolina Urologic Research Center, University of Pittsburgh, Virginia Oncology Associates, U-M Rogel Cancer Center, University of Pittsburgh Medical Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Arizona Oncology, University of Arizona Cancer Center, Weill Cornell Medicine, Brown University, Tulane University, Virginia Cancer Specialists, Progenics Pharmaceuticals (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1872007843